Skip to main content Accessibility help
×
Home

Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients

  • JULIANA G. CARNEIRO (a1) (a2), PATRICIA G. COUTO (a2), LUCIANA BASTOS-RODRIGUES (a2), MARIA APARECIDA C. BICALHO (a3), PAULA V. VIDIGAL (a4), ALYNE VILHENA (a5), NILSON F. AMARAL (a5), ALLEN E. BALE (a6), EITAN FRIEDMAN (a7) and LUIZ DE MARCO (a2)...

Summary

Lung cancer is the leading global cause of cancer-related mortality. Inter-individual variability in treatment response and prognosis has been associated with genetic polymorphisms in specific genes: EGFR, KRAS, BRAF, PTEN and TTF-1. Somatic mutations in EGFR and KRAS genes are reported at rates of 15–40% in non-small cell lung cancer (NSCLC) in ethnically diverse populations. BRAF and PTEN are commonly mutated genes in various cancer types, including NSCLC, with PTEN mutations exerting an effect on the therapeutic response of EGFR/AKT/PI3K pathway inhibitors. TTF-1 is expressed in approximately 80% of lung adenocarcinomas and its positivity correlates with higher prevalence of EGFR mutation in this cancer type. To determine molecular markers for lung cancer in Brazilian patients, the rate of the predominant EGFR, KRAS, BRAF and PTEN mutations, as well as TTF-1 expression, was assessed in 88 Brazilian NSCLC patients. EGFR exon 19 deletions (del746–750) were detected in 3/88 (3·4%) patients. Activating KRAS mutations in codons 12 and 61 were noted in five (5·7%) and two (2·3%) patients, respectively. None of the common somatic mutations were detected in either the BRAF or PTEN genes. TTF-1 was overexpressed in 40·7% of squamous-cell carcinoma (SCC). Our findings add to a growing body of data that highlights the genetic heterogeneity of the abnormal EGFR pathway in lung cancer among ethnically diverse populations.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: Av. Alfredo Balena 190, room 325, Belo Horizonte 30130-100, Brasil. Tel: +55 (31) 3409-9134. Fax: +55 (31) 3409-9134. E-mail: Ldemarco@ufmg.br

References

Hide All
Amoedo, N. D., Castelo-Branco, M. T., Paschoal, M. E., Pezzuto, P., Esperança, A. B., Rumjanek, V. M. & Rumjanek, F. D. (2009). Expression of ABC transporters, p53, Bax, Bcl-2 in an archival sample of non-small cell lung cancer bearing a deletion in the EGFR gene. International Journal of Molecular Medicine 23, 609614.
Arrieta, O., Cardona, A. F., Bramuglia, G. F., Gallo, A., Campos-Parra, A. D., Serrano, S., Castro, M., Avilés, A., Amorin, E., Kirchuk, R., Cuello, M., Borbolla, J., Riemersma, O., Becerra, H. & Rosell, R. (2011). Genotyping non-small cell lung cancer (NSCLC) in Latin America. Journal of Thoracic Oncology 6, 19551959.
Bastos-Rodrigues, L., Pimenta, J. R. & Pena, S. D. (2006). The genetic structure of human populations studied through short insertion-deletion polymorphisms. Annals of Human Genetics 70, 658665.
Berghmans, T., Mascauxa, C., Hallerb, A., Meerta, A. P., Van Houttec, P. & Sculier, J. P. (2008). EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer 62, 3544.
Borràs, E., Jurado, I., Hernan, I., Gamundi, M. J., Dias, M., Martí, I., Mañé, B., Arcusa, A., Agúndez, J. A., Blanca, M. & Carballo, M. (2011). Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing. BMC Cancer 11, 406.
Brevet, M., Johnson, M. L., Azzoli, C. G. & Ladanyi, M. (2011). Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73, 96102.
Cantley, L. C. & Neel, B. G. (1999). New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proceedings of the National Academy of Sciences USA 96, 42404245.
Cantwell-Dorris, E. R. (2011). BRAFV600E: Implications for carcinogenesis and molecular therapy. Molecular Cancer Therapeutics 10, 385394.
Cote, M. L., Kardia, S. L., Wenzlaff, A. S., Ruckdeschel, J. C. & Schwartz, A. G. (2005). Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer. JAMA 293, 30363042.
Cote, M. L., Haddad, R. & Edwards, D. J. (2011). Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. Journal of Thoracic Oncology 6, 627630.
Dearden, S., Stevens, J., Wu, Y. L. & Blowers, D. (2013). Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Annals of Oncology 24, 23712376.
Dhomen, N. & Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematology/Oncology Clinics of North America 23, 529545.
Endersby, R. & Baker, S. J. (2008). PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 54165430.
Forgacs, E., Biesterveld, E. J., Sekido, Y., Fong, K., Muneer, S., Wistuba, I. I., Milchgrub, S., Brezinschek, R., Virmani, A., Gazdar, A. F. & Minna, J. D. (1998). Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17, 15571565.
Gaughan, E. M. & Costa, D. B. (2011). Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Therapeutic Advances in Medical Oncology 3, 113125.
Girard, N. (2013). Other signalization targets. Target Oncology 8, 6977.
Haiman, C. A., Stram, D. O., Wilkens, L. R., Pike, M. C., Kolonel, L. N., Henderson, B. E. & Le Marchand, L. (2006). Ethnic and racial differences in the smoking-related risk of lung cancer. New England Journal of Medicine 354, 333342.
Han, S. W., Kim, T. Y., Jeon, Y. K., Hwang, P. G., Im, S. A., Lee, K. H., Kim, J. H., Kim, D. W., Heo, D. S., Kim, N. K., Chung, D. H. & Bang, Y. J. (2006). Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clinical Cancer Research 12, 25382544.
Heigener, D. F. & Reck, M. (2011). Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: impact on treatment beyond gefitinib and erlotinib. Advances in Therapy 28, 126133.
Hunt, J. D., Strimas, A., Eyer, M., Haddican, M., Luckett, B. G., Ruiz, B., Axelrad, T. W., Backes, W. L. & Fontham, E. T. (2002). Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. Cancer Epidemiology, Biomarkers and Prevention 11, 14051412.
Irmer, D., Funk, J. O. & Blaukat, A. (2007). EGFR kinase domain mutations – functional impact and relevance for lung cancer therapy. Oncogene 26, 56935701.
Jin, G., Kim, M. J., Jeon, H. S., Choi, J. E., Kim, D. S., Lee, E. B., Cha, S. I., Yoon, G. S., Kim, C. H., Jung, T. H. & Park, J. Y. (2010). PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer 69, 279283.
Kadara, H., Kabbout, M. & Wistuba, I. (2011). Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology 17, 5065.
Kawaguchi, T., Matsumura, A., Fukai, S., Tamura, A., Saito, R., Zell, J. A., Maruyama, Y., Ziogas, A., Kawahara, M. & Ignatius, S. H. (2010). Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. Journal of Thoracic Oncology 5, 10011010.
Keedy, V. L., Temin, S., Somerfield, M. R., Beasley, M. B., Johnson, D. H., McShane, L. M., Milton, D. T., Strawn, J. R., Wakelee, H. A. & Giaccone, G. (2011). American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. Journal of Clinical Oncology 29, 21212127.
Kondo, M., Yokoyama, T., Fukui, T., Yoshioka, H., Yokoi, K., Nagasaka, T., Imaizumi, K., Kume, H., Hasegawa, Y., Shimokata, K. & Sekido, Y. (2005). Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50, 385391.
Kumar, K., Brim, H., Giardiello, F., Smoot, D. T., Nouraie, M., Lee, E. L. & Ashktorab, H. (2009). Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clinical Cancer Research 15, 11551161.
Lahiri, D. K. & Nurnberger, J. I. (1991). A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research 11, 5444.
Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., Park, T. I., Kim, C. H., Jung, T. H. & Park, J. Y. (2010). Somatic mutations in EGFR signaling pathway genes. Journal of Thoracic Oncology 5, 17341740.
Leidner, R. S., Fu, P., Clifford, B., Hamdan, A., Jin, C., Eisenberg, R., Boggon, T. J., Skokan, M., Franklin, W. A., Cappuzzo, F., Hirsch, F. R., Varella-Garcia, M. & Halmos, B. (2009). Genetic abnormalities of the EGFR pathway in African American patients with non–small-cell lung cancer. Journal of Clinical Oncology 27, 56205626.
Li, G., Zhao, J., Peng, X., Liang, J., Deng, X. & Chen, Y. (2012). The mechanism involved in the loss of PTEN expression in NSCLC tumor cells. Biochemical and Biophysical Research Communications 418, 547552.
Li, T., Kung, H. J., Mack, P. C. & Gandara, D. R. (2013). Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. Journal of Clinical Oncology 31, 10391049.
Maeshima, A. M., Omatsu, M., Tsuta, K., Asamura, H. & Matsuno, Y. (2008). Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. Pathology International 58, 3137.
Marchetti, A., Felicioni, L., Malatesta, S., Grazia Sciarrotta, M., Guetti, L., Chella, A., Viola, P., Pullara, C., Mucilli, F. & Buttitta, F. (2011). Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. Journal of Clinical Oncology 29, 357435479.
Matsuo, K., Ito, H., Yatabe, Y., Hiraki, A., Hirose, K., Wakai, K., Kosaka, T., Suzuki, T., Tajima, K. & Mitsudomi, T. (2007). Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Science 98, 96101.
Maxwell, G. L., Risinger, J. I., Hayes, K. A., Alvarez, A. A., Dodge, R. K., Barrett, J. C. & Berchuck, A. (2000). Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clinical Cancer Research 6, 29993005.
Miller, S. A., Dykes, D. D. & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research 16, 1215.
Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saij, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., Nishiwaki, Y., Ohe, Y., Yang, J., Chewaskulyong, B., Jiang, H., Duffield, E. L., Watkins, C. L., Armour, A. A. & Fukuoka, M. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine 361, 947957.
Murray, S., Timotheadou, E., Linardou, H., Vrettou, A. V., Kostopoulos, I., Skrickova, J., Papakostantinou, C., Christodoulou, C., Pectasides, D., Samantas, E., Papakostas, P., Skarlos, D. V., Kosmidis, P. & Fountzilas, G. (2006). Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients. Lung Cancer 52, 225233.
Ordóñez, N. G. (2012). Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Applied Immunohistochemistry and Molecular Morphology 20, 525530.
Oxnard, G. R., Binder, A., & Jänne, P. A. (2013). New targetable oncogenes in non-small-cell lung cancer. Journal of Clinical Oncology 31, 10971104.
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M. J., Sellers, W. R., Johnson, B. E. & Meyerson, M. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 14971500.
Pan, Q., Pao, W., Ladanyi, M. (2005). Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. The Journal of Molecular Diagnostics 7, 396403.
Pandolfi, P. P. (2008). P-TEN exciting years: from the cytosol to the nucleus and back to keep cancer at bay. Oncogene 27, 5386.
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G. & Varmus, H. E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2, e17.
Pena, S. D., Bastos-Rodrigues, L., Pimenta, J. R. & Bydlowski, S. P. (2009). DNA tests probe the genomic ancestry of Brazilians. Brazilian Journal of Medical and Biological Research 42, 870876.
Pratilas, C. A., Hanrahan, A. J., Halilovic, E., Persaud, Y., Soh, J., Chitale, D., Shigematsu, H., Yamamoto, H., Sawai, A., Janakiraman, M., Taylor, B. S., Pao, W., Toyooka, S., Ladanyi, M., Gazdar, A., Rosen, N. & Solit, D. B. (2008). Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Research 68, 93759383.
Reinersman, J. M., Johnson, M. L., Riely, G. J., Chitale, D. A., Nicastri, A. D., Soff, G. A., Schwartz, A. G., Sima, C. S., Ayalew, G., Lau, C., Zakowski, M. F., Rusch, V. W., Ladanyi, M. & Kris, M. G. (2011). Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of Thoracic Oncology 6, 2831.
Reungwetwattana, T., Weroha, S. J. & Molina, J. R. (2012). Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clinical Lung Cancer 13, 252266.
Riely, G. J., Politi, K. A., Miller, V. A. & Pao, W. (2006). Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clinical Cancer Research 12, 72327241.
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., Miller, V. A. & Ladanyi, M. (2008). Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clinical Cancer Research 14, 57315734.
Riely, G. J., Marks, J. & Pao, W. (2009). KRAS mutations in non-small cell lung cancer. Proceedings of the American Thoracic Society 6, 201205.
Rosell, R., Moran, C., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., Insa, A., Massuti, B., Gonzalez-Larriba, J. L., Paz-Ares, L., Bover, I., Garcia-Campelo, R., Moreno, M. A., Catot, S., Rolfo, C., Reguart, N., Palmero, R., Sánchez, J. M., Bastus, R., Mayo, C., Bertran-Alamillo, J., Molina, M. A., Sanchez, J. J. & Taron, M. (2009). Screening for epidermal growth factor receptor mutations in lung cancer. New England Journal of Medicine 361, 958967.
Sasaki, H., Kawano, O., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M. & Fujii, Y. (2006). Uncommon V599E BRAF mutations in Japanese patients with lung cancer. Journal of Surgical Research 133, 203206.
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., Fujisawa, T., Feng, Z., Roth, J. A., Herz, J., Minna, J. D. & Gazdar, A. F. (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute 97, 339346.
Simpson, L. & Parsons, R. (2001). PTEN: life as a tumor suppressor. Experimental Cell Research 264, 2941.
Su, Z., Dias-Santagata, D., Duke, M., Hutchinson, K., Lin, Y. L., Borger, D. R., Chung, C. H., Massion, P. P., Vnencak-Jones, C. L., Iafrate, A. J. & Pao, W. (2011). A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non–small-cell lung cancer. Journal of Molecular Diagnostics 13, 7484.
Suda, K., Tomizawa, K. & Mitsudomi, T. (2010). Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Review 29, 4960.
Tang, J. M., He, Q. Y., Guo, R. X. & Chang, X. J. (2006). Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51, 181191.
Tang, M., Iijima, M., Kamimura, Y., Chen, L., Long, Y. & Devreotes, P. (2011). Disruption of PKB signaling restores polarity to cells lacking tumor suppressor PTEN. Molecular Biology of the Cell 22, 437447.
Tapia, C., Savic, S., Bihl, M., Rufle, A., Zlobec, I., Terracciano, L. & Bubendorf, L. (2009). EGFR mutation analysis in non-small-cell lung cancer: experience from routine diagnostics. Der Pathologe 30, 384392. [In German]
Travis, W. D., Brambilla, E. & Riely, G. J. (2013). New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. Journal of Clinical Oncology 31, 9921001.
Vlastos, F., Zinszner, J., Hussenet, T., du Manoir, S., Vordonis, L., Nikolakopoulou, S., Hardavella, G., Lacomme, S., Vignaud, J. M. & Martinet, N. (2010). Mapping EGFR1 mutations in patients with lung adenocarcinoma. Diagnostic Molecular Pathology 19, 209217.
Wislez, M., Antoine, M., Baudrin, L., Poulot, V., Neuville, A., Pradere, M., Longchampt, E., Isaac-Sibille, S., Lebitasy, M. P. & Cadranel, J. (2010). Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 68, 185191.
Xing, M. (2005). BRAF mutation in thyroid cancer. Endocrine Related Cancer 12, 245262.
Yatabe, Y., Kosaka, T., Takahashi, T. & Mitsudomi, T. (2005). EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. American Journal of Surgical Pathology 29, 633639.
Yokomizo, A., Tindall, D. J., Drabkin, H., Gemmill, R., Franklin, W., Yang, P., Sugio, K., Smith, D. I. & Liu, W. (1998). PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475479.
Zuo, Z., Chen, S. S., Chandra, P. K., Galbincea, J. M., Soape, M., Doan, S., Barkoh, B. A., Koeppen, H., Medeiros, L. J. & Luthra, R. (2009). Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Modern Pathology 22, 10231031.

Related content

Powered by UNSILO

Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients

  • JULIANA G. CARNEIRO (a1) (a2), PATRICIA G. COUTO (a2), LUCIANA BASTOS-RODRIGUES (a2), MARIA APARECIDA C. BICALHO (a3), PAULA V. VIDIGAL (a4), ALYNE VILHENA (a5), NILSON F. AMARAL (a5), ALLEN E. BALE (a6), EITAN FRIEDMAN (a7) and LUIZ DE MARCO (a2)...

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.